← Back to Search

Treatment for Epilepsy

N/A
Waitlist Available
Research Sponsored by Mid-Atlantic Epilepsy and Sleep Center, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up seizure count per 28 days, baseline 52 weeks, maintanance period 52 weeks
Awards & highlights

Summary

To evaluate the efficacy, safety and tolerability of cenobamate as adjunctive treatment of refractory focal epilepsy

Eligible Conditions
  • Epilepsy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~seizure count per 28 days, baseline 52 weeks, maintanance period 52 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and seizure count per 28 days, baseline 52 weeks, maintanance period 52 weeks for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
>75% seizure frequency reduction
The seizure frequency per 28 days.
seizure freedom rate
+2 more
Secondary study objectives
driving status
median seizure frequency reduction
quality of life change
+2 more

Find a Location

Who is running the clinical trial?

Mid-Atlantic Epilepsy and Sleep Center, LLCLead Sponsor
8 Previous Clinical Trials
316 Total Patients Enrolled
4 Trials studying Epilepsy
68 Patients Enrolled for Epilepsy
~19 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top